subject area of
- A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients. Journal Articles
- A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group Journal Articles
- A phase II trial of ZD1839 (Iressa™) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer Journal Articles
- Challenges to Implementation of an Epidermal Growth Factor Receptor Testing Strategy for Non–Small-Cell Lung Cancer in a Publicly Funded Health Care System Journal Articles
- Osimertinib in UntreatedEGFR-Mutated Advanced Non–Small-Cell Lung Cancer Journal Articles
- Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC Journal Articles
- RIPK2 Dictates Insulin Responses to Tyrosine Kinase Inhibitors in Obese Male Mice Journal Articles
- Severe Bronchorrhea in a Patient with Bronchioloalveolar Carcinoma Journal Articles
- Targeting the epidermal growth factor receptor in non-small-cell lung cancer: Who, which, when, and how? Journal Articles
- Tyrosine kinase inhibitors of Ripk2 attenuate bacterial cell wall-mediated lipolysis, inflammation and dysglycemia Journal Articles
- Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: a systematic review. Journal Articles